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Akkermansia muciniphila uses 
human milk oligosaccharides 
to thrive in the early life conditions 
in vitro
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Akkermansia muciniphila is a well-studied anaerobic bacterium specialized in mucus degradation 
and associated with human health. Because of the structural resemblance of mucus glycans and 
free human milk oligosaccharides (HMos), we studied the ability of A. muciniphila to utilize human 
milk oligosaccharides. We found that A. muciniphila was able to grow on human milk and degrade 
HMos. Analyses of the proteome of A. muciniphila indicated that key-glycan degrading enzymes 
were expressed when the bacterium was grown on human milk. our results display the functionality 
of the key-glycan degrading enzymes (α-l-fucosidases, β-galactosidases, exo-α-sialidases and 
β-acetylhexosaminidases) to degrade the HMO-structures 2′-FL, LNT, lactose, and LNT2. The 
hydrolysation of the host-derived glycan structures allows A. muciniphila to promote syntrophy with 
other beneficial bacteria, contributing in that way to a microbial ecological network in the gut. Thus, 
the capacity of A. muciniphila to utilize human milk will enable its survival in the early life intestine and 
colonization of the mucosal layer in early life, warranting later life mucosal and metabolic health.
Akkermansia muciniphila is a Gram-negative anaerobe, belonging to the phylum  Verrucomicrobia1, that colonizes 
the mucus layer of the human gastrointestinal (GI)  tract2. A. muciniphila is associated with a healthy mucosal 
layer and metabolic state as it has been inversely correlated with  obesity3,4, metabolic diseases (Type 2 diabetes)5 
as well as intestinal disorders (inflammatory bowel disease (IBD) and appendicitis)6–8. This intestinal bacterium 
has an extraordinary capacity to degrade mucin as the sole energy, carbon and nitrogen source and convert this 
polymer into mostly acetate and  propionate2.
Akkermansia muciniphila is a common member of the adult and infant  microbiota9. The infant’s gut colonisa-
tion with A. muciniphila has been detected from the first month of life, with a continuously increasing abundance 
during  adulthood9,10. Additionally, A. muciniphila was detected in the breast tissue of lactating mothers as well 
as in human  milk11–13. Interestingly, two studies have reported that A. muciniphila was found to be lower in 
abundance in the breast-fed infants compared to formula-fed  infants14,15. In a more recent study with 98 Swed-
ish infants though, the abundance and the prevalence of A. muciniphila increased between 4 and 12 months old, 
and showed no significant change depending on delivery mode or type of  feeding16. Early in life, mother’s milk 
is often the only source of nutrients and dietary glycans for infants, and it is considered the best nourishment 
for the development of the new-born17. The glycans in human milk are named human milk oligosaccharides 
(HMOs), and they have proven to have an impact on infant intestinal microbiota  composition18. Human milk 
contains 5–15 g/l HMOs, with more than 200 different HMO structures reported of which 100 have been suc-
cessfully  elucidated19–22. The presence and the quantity of these HMOs structures vary per individual and are 
related to the genetic Secretor and Lewis status of the  mother23. The major building blocks of monosaccharides 
present in HMOs are d-glucose (Glc), d-galactose (Gal), N-acetyl-glucosamine (GlcNAc), l-fucose (Fuc), and 
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N-acetylneuraminic acid (sialic acid, Neu5Ac)24. These sugars form a number of complex glycans containing 
well-defined different glycosidic linkages resulting in both linear and branched  structures25. In human milk 70% 
of the oligosaccharides are fucosylated and 30% are  sialylated19,26. HMOs can function as prebiotic substrates by 
promoting and stimulating the growth of beneficial bacteria such as  bifidobacteria27. Nowadays, supplementa-
tion of infant formulae with HMOs, such as 2′-FL and LNnT, is gaining more and more interest to bring infant 
formula composition even closer to human  milk28. In addition, some of these oligosaccharide molecules inhibit 
the colonisation of pathogenic bacteria by acting as receptor analogues and binding to the bacterial  surface24.
The resemblance of glycosidic structure between HMOs and mucin glycans might explain why some bacteria 
are capable of utilising both human milk glycans and host mucosal glycans (mucins)29,30. Mucins are the main 
structural components of the mucus layer that covers the gut epithelium surface. Mucins’ protein core consists 
of 80% carbohydrates, mainly N-acetylgalactosamine, N-acetylglucosamine, fucose, galactose and sialic  acid31,32. 
The mucus layer in the human gut is divided into an outer layer, which provides a nutrient-rich habitat for the 
microbiota, and an inner layer, which is firmly attached to the surface of the epithelium and virtually free of 
 bacteria33. In the human gut, A. muciniphila has the extraordinary capacity to degrade mucins by employing 
a large arsenal of sulfatases and glycoside hydrolases (GH) for effective metabolism of mucin glycans such as 
α-fucosidases, α-sialidases, β-galactosidases, β-acetylhexosaminidases, and α-acetylglucosaminidases1,34.
We hypothesize that the presence of A. muciniphila in the early life intestine is the result of its ability to 
use its mucin degrading machinery to breakdown HMOs. Its presence in the early life intestine will enhance 
microbial ecologic network formation and healthy microbial colonisation of the mucosal layer warranting later 
life health. To assess this, we tested the ability of A. muciniphila to grow on human milk and different HMOs. 
Subsequently, we identified the HMOs structures that A. muciniphila was able to break down and the enzymes 
responsible for the degradation.
Results
A. muciniphila grows on human milk via HMos utilisation. Incubation of A. muciniphila on human 
milk resulted in growth (Fig. 1a). The fermentation profile of the cultures showed production of acetate, pro-
pionate, and succinate (Fig. 1b,c) as well as release of glucose and galactose due to the utilisation of the lactose 
that is already present in the breast milk and in the HMOs (Fig. 2a). The amounts of produced short-chain 
fatty acids (SCFAs) and utilised sugars are shown in the Supplementary Table 2. We next sought to investigate 
which HMOs structures were utilised by A. muciniphila during the growth on human milk. The HMOs profile 
showed utilisation of neutral trioses (2′-fucosyllactose [2′-FL] and 3-fucosyllactose [3-FL]), tetraoses (difucosyl-
lactose [DFL], lacto-N-tetraose [LNT], lacto-N-neotetraose [LNnT]), pentaoses (lacto-fucopentaose I [LNFP I], 
Figure 1.  A. muciniphila growth in human milk. (a) A. muciniphila growth in human milk or porcine mucin 
as the sole carbon and nitrogen source. Error bars indicate the standard error of qPCR for three biological 
replicates. A. muciniphila SCFAs production (b) in human milk and (c) in mucin. Error bars indicate the 
standard deviation of three biological replicates.
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lacto-fucopentaose II [LNFP II], lacto-fucopentaose III [LNFP III], lacto-fucopentaose V [LNFP V]), and acidic 
trioses (3′-siallylactose [3′-SL], 6′-sialyllactose [6′-SL]) (Fig. 3). All measured HMOs were reduced at least two-
fold (Fig. 3). The HMO profile analysis revealed that A. muciniphila utilises almost completely 2′-FL and 3′-SL 
present in human milk (99.65% and 97.49%, respectively) (Fig. 3).  
Next, it was tested whether these nutritional components by themselves could promote the growth of A. 
muciniphila. Incubation of A. muciniphila with pure 2′-FL or 3′-SL (10 mM) resulted in growth (Supplementary 
Fig. 1) and demonstrated the release of lactose from both 2′-FL or 3′-SL (Fig. 2b,c). The resulting lactose was 
further broken down to its monosaccharides (glucose and galactose). Growth on 2′-FL resulted in the production 
Figure 2.  A. muciniphila HMO degradation. (a) Human Milk, (b) 2′-fucosyllactose (2′-FL), and (c) 
3′-sialyllactose (3′-SL). Error bars represent the standard deviation of three biological replicates.
Figure 3.  Utilisation of HMOs structures by A. muciniphila incubated in 10% human milk. The numbers above 
each bar indicate the degradation percentage of each HMO. Error bars represent the error propagation of three 
biological replicates.
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of 1,2-propanediol (5.95 ± 0.42 mM), which is an indication of the fucose metabolism by A. muciniphila. The 
liberated neuraminic acid from 3′-SL was not further catabolised by the bacterium. The overall fermentation 
efficiency was determined by calculating the carbon balance; the recovery of carbon atoms at 48 h of 2′-FL and 
3′-SL was 86.58 and 82.58% respectively (Supplementary Table 3a). Furthermore, the amounts of produced 
short-chain fatty acids (SCFAs) and utilised sugars of A. muciniphila grown in 2′-FL and 3′-SL are shown in the 
Supplementary Table 3b.
A. muciniphila exhibits glycoside hydrolase expression during growth on human milk. We 
performed proteomic analysis on the A. muciniphila cultures grown on human milk to identify the active 
enzymes that could contribute to the degradation of human milk and its components. A total of 832 bacte-
rial proteins were detected after growth on human milk. We mined the proteome data for proteins predicted 
to participate in carbohydrate metabolism and this returned 109 proteins and over half of them (62 proteins) 
are primarily involved in this specific metabolic pathway (Table 1). A. muciniphila possesses 58 proteins that 
encode for glycoside hydrolases (GHs). In our results, we detected 43 GHs and 19 of these proteins belong to 
the six GH families (GH2, GH20, GH29, GH33, GH35 and GH95) that target the most common linkages found 
within HMOs. We identified four β-galactosidases that belong to GH2 family, two GH35 β-galactosidases, seven 
β-hexosaminidases from GH family 20, two GH29 α-fucosidases, two GH95 α-fucosidases and two exo-alpha 
sialidases from GH33 (Table  1). Therefore, we proposed A. muciniphila employed the fucosidases to release 
the terminal α1-2/3/4 linked fucose from the fucosylated HMOs; 2′-FL (Fucα1-2Galβ1-4Glc), 3-FL (Galβ1-
4Fucα1-3Glc), DFL (Fucα1-2Galβ1-4 Fucα1-3Glc), LNFPI (Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc), LNFP II 
(Galβ1-3Fucα1-4GlcNAcβ1-3Galβ1-4Glc), LNFP III (Galβ1-4Fucα1-3GlcNAcβ1-3Galβ1-4Glc) and LNFP V 
(Galβ1-3GlcNAcβ1-3Galβ1-4Fucα1-3Glc). Additionally, A. muciniphila expressed the 2 sialidases that can lib-
erate the α2-3 and α2-6 linked sialic acid from the sialylated glycans 3′-SL (Neu5Acα2-3Galβ1-4Glc) and 6′-SL 
(Neu5Acα2-6Galβ1-4Glc) present in the human milk. Furthermore, the hydrolysis of the terminal β1-3 and 
β1-4 galactose residues found in the HMOs structures; LNT (Galβ1-3GlcNAcβ1-3Galβ1-4Glc), LNnT (Galβ1-
4GlcNAcβ1-3Galβ1-4Glc), lactose (Galβ1-4Glc), as well as LNFP II, LNFP III and LNFP V can be the result of 
β-galactosidases’ action expressed by A. muciniphila during growth on human milk. A. muciniphila expressed 
also 7 β-hexosaminidases which are responsible for releasing the terminal β1-3 and β1-4N-acetylglucosamine 
(GlcNAc) bound to glycan structures. However, GlcNAc is usually found as terminal sugar in HMO glycans but 
rather is often decorated by other monosaccharides (galactose, fucose, sialic acid). Thus, A. muciniphila might 
use its hexosaminidases to degrade simpler HMOs such as Lacto-N-biose (Galβ1-3GlcNAc), LNT2 (GlcNAcβ1-
3Galβ1-4Glc). In addition, A. muciniphila expressed some of the necessary enzymes to metabolise the liberated 
monosaccharides from the HMOs degradation. A. muciniphila employs, for example, Amuc_1833 (l-fucose 
transporter-fucP), Amuc_1832 (l-fucose isomerase-fucI), Amuc_1830 (l-fuculokinase-fucK), and Amuc_1829 
(class II aldolase-fucA) for the utilisation of the liberated fucose to 1,2-propanediol. Furthermore, Amuc_0969 
(Galactokinase) participates in the first steps of the galactose metabolism by converting the free galactose into 
α-d-galactose-1-phosphate, while Amuc_0097 (ROK family protein) can be used by A. muciniphila to convert 
glucose to α-d-glucose-6-phosphate during the first step of the glycolysis pathway (Supplementary Table  4). 
Nevertheless, A. muciniphila lacks all the necessary enzymes for the sialic acid utilisation, since no expression of 
these enzymes was observed in the proteome data. These data demonstrate that A. muciniphila has the enzymatic 
capacity to utilise a broad range of HMOs as well as their constituents.
characterization of A. muciniphila HMo degrading enzymes. The next step of the study was con-
cerned with the characterisation of A. muciniphila enzymes that are effective in HMO-degradation. Therefore, 
we assessed five glycan-degrading enzymes identified by proteomics that are also predicted to hydrolyse the 
glycosidic bonds of lactose and the HMOs; 2′-FL, LNT and LNT2 (Table 1); one α-fucosidase (Amuc_0010), 
two β-galactosidases (Amuc_0771 and Amuc_1686) and two β-acetylhexosaminidases (Amuc_0369 and 
Amuc_2136). The enzymatic activity of the recombinant proteins was first assessed using synthetic substrates 
(Table 2). Amuc_0771 and Amuc_2136 showed a pH optimum of 5.0, while Amuc_0010 and Amuc_0369 dis-
played optimal pH at 5.6. For Amuc_1686 the rate of pNP release (μΜ min−1) was similar for all the different 
pH values that were tested (Supplementary Fig. 2). pH 5.0 was selected as the optimal pH for this enzyme. Each 
enzyme’s optimal pH and temperature of 37  °C were used to assess the kinetic parameters of these proteins 
against synthetic substrates pNP-α-l-Fuc, pNPG and GlcNAc-β-pNP (Table 2 and Supplementary Fig. 3). The 
α-l-fucosidase (Amuc_0010) showed a KM 839 ± 46.72 μM against pNP-Fucose. Both β-acetylhexosaminidases 
(Amuc_0369 and Amuc_2136) exhibited hexosaminidase activity by cleaving GlcNAc from pNP-GlcNAc. A 
lower KM for Amuc_0369 (322.37 ± 43.64  μM) was observed than Amuc_2136 (714.55 ± 47.96  μM). Cleav-
age of galactose from pNPG was detected with β-galactosidases (Amuc_0771 and Amuc_1686). Amuc_0771 
showed higher KM (2,599 ± 565.27 μΜ) than Amuc_1686 (319.40 ± 259.30 μΜ). The ability of the α-l-fucosidase 
(Amuc_0100) for cleaving α1-2 linked fucose from 2′-FL (Fucα1-2Galβ1-4Glc) was assessed (Table  2 and 
Supplementary Fig. 4). The enzyme exhibited a high KM and lower activity (152.08 min−1 kcat) against 2′-FL 
than pNP-Fuc (2.27 × 104 min−1 kcat). The activity of β-acetylhexosaminidases (Amuc_0369 and Amuc_2136) 
on the HMOs, LNT (Galβ1-3GlcNAcβ1-3Galβ1-4Glc) and LNT2 (GlcNAcβ1-3Galβ1-4Glc) was assessed as 
well. The substrate and product specificity were monitored by HPAEC-PAD. For both enzymes no liberation 
of GlcNAc was observed in the presence of LNT, while both A. muciniphila β-acetylhexosaminidases were 
able to cleave the terminal GlcNAc off lactose resulting in LNT2. Amuc_0369 exhibited a kcat 1.42 × 104 min−1 
and a KM 3,980 ± 210.30  μM against LNT2. Amuc_2136 showed higher substrate affinity than Amuc_0369 
(2,435.82 ± 289.51  μM KM) but no significant difference in the catalytic activity (1.45 × 104  min−1 kcat). The 
β-galactosidases (Amuc_0771 and Amuc_1686) were tested for their capability to break down galactosidic link-
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Continued
CAZy Locus tag Protein
Average_LFQ_
Human Milk KO ID Pathway
GH20
Amuc_2136 Glycoside hydrolase, 
family 20, catalytic core 8.64
ko00511;ko00520
Other glycan degradation; 
Amino sugar and 
nucleotide sugar 
metabolism
GH2
Amuc_0824 Glycoside hydrolase family 
2 TIM barrel 8.55
ko00052;ko00511 Galactose metabolism; 
Other glycan degradation
GH2
Amuc_0290 Glycoside hydrolase family 
2 sugar binding 8.43
ko0005 2;ko00511 Galactose metabolism; 
Other glycan degradation
GT35
Amuc_0235 Alpha-glucan 
phosphorylase 8.42 ko00500
Starch and sucrose 
metabolism
GH29
Amuc_0392 Coagulation factor 5/8 type 
domain protein 8.23 ko00511 Other glycan degradation
CE11
Amuc_1918
Beta-hydroxyacyl-(Acyl-
carrier-protein) 
dehydratase FabZ 8.21
ko00061;ko00540
Amuc_0155
Phosphoglucomutase/phos
phomannomutase 
alpha/beta/alpha domain I 8.19
ko00051;ko00520
Fructose and mannose 
metabolism; Amino sugar 
and nucleotide sugar 
metabolism
GH31
Amuc_1008 Glycoside hydrolase family 
31 8.16
GH109
Amuc_0017 Glycosyl hydrolase family 
109 protein 1 8.14
GH84
Amuc_0052 Hyalurononglucosaminidas
e 8.09 ko00531
Glycosaminoglycan 
degradation
CE9
Amuc_0948 N-acetylglucosamine-6-
phosphate deacetylase 7.84 ko00520
Amino sugar and 
nucleotide sugar 
metabolism
GT4
Amuc_1869 Glycosyl transferase group 
1 7.83
GH2
Amuc_0539 Glycoside hydrolase family 
2 sugar binding 7.76
Amuc_1436
Malate dehydrogenase 7.74
ko00020;ko006
20;ko00630;ko00680
Citrate Cycle (TCA cycle); 
Pyruvate metabolism; 
Glycoxylate and 
dicarboxylate metabolism; 
Methane metabolism
GH89
Amuc_1220 Alpha-N-
acetylglucosaminidase 7.73
GH95
Amuc_1120 Putative uncharacterized 
protein 7.72 ko00511 Other glycan degradation
GH36
Amuc_0216 Putative uncharacterized 
protein 7.66
GH13
Amuc_1751 Glycoside hydrolase family 
13 domain protein 7.65 ko00500
Starch and sucrose 
metabolism
Amuc_1543
Formate acetyltransferase 7.54
ko00620;ko006
40;ko00650
Pyruvate metabolism; 
Propanoate metabolism; 
Butanoate metabolism
GH57
Amuc_1868 Glycoside hydrolase family 
57 7.42 ko00500
Starch and sucrose 
metabolism
GH35, 
CBM32
Amuc_1686
Beta-galactosidase 7.37 ko00052 Galactose metabolism
GH110,CBM
51
Amuc_0480
Alpha-1,3-galactosidase B 6.90
GH33
Amuc_0625
Exo-alpha-sialidase 6.89 ko00511 Other glycan degradation
GH98
Amuc_1438
Glycosyl hydrolase family 
98 putative carbohydrate 
binding module 6.86
GH35
Amuc_0771
Beta-galactosidase 6.79
ko00052;ko00511 Galactose metabolism; 
Other glycan degradation
GH16
Amuc_0724 Glucan endo-1,3-beta-D-
glucosidase 6.73
GH33
Amuc_1835
Exo-alpha-sialidase 6.70 ko00511 Other glycan degradation
GH123.CBM
32
Amuc_0803 Coagulation factor 5/8 type 
domain protein 6.66
CBM50
Amuc_0821 Peptidoglycan-binding 
LysM 6.30
GH20
Amuc_1032 Beta-N-
acetylhexosaminidase 6.29
CE4
Amuc_1500
Polysaccharide deacetylase 6.27
GH95
Amuc_0186 Glycoside hydrolase family 
95 6.24
GH89
Amuc_0060 Alpha-N-
acetylglucosaminidase 6.18
GT28
Amuc_0659
UDP-N-
acetylglucosamine--N-
acetylmuramyl-
(pentapeptide) 6.18 ko00550 Peptidoglycan biosynthesis
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ages from the HMO, LNT (Galβ1-3GlcNAcβ1-3Galβ1-4Glc) and lactose (Galβ1-4Glc). Amuc_0771 showed a 
kcat 4.42 × 103 min−1 and a KM 1,223 ± 171.7 μM against LNT (β1-3) (Table 2). In addition, Amuc_0771 was able 
to release 711 μΜ of glucose and 936 μΜ of galactose when was incubated in 2,000 μΜ of lactose overnight 
(Supplementary Fig. 5). However, the reaction in lactose was slow and therefore we were not able to assess the 
kinetics of Amuc_0771. The enzyme displayed cleaving capacity for both β1-3 and β1-4 glycosidic linkages, 
but with higher substrate specificity towards β1-3 linkages. The other β-galactosidase (Amuc_1686) showed no 
enzymatic activity against LNT or lactose. E. coli BL21 Rosetta strain harbouring the pCDF1-b empty vector 
induced with IPTG was used as negative control and it was incubated overnight in 2 mM LNT, 2′-FL, lactose and 
5 mM LNT2 showing no activity at all, against these substrates (Supplementary Fig. 7).
pyrophosphoryl-
undecaprenol N-
acetylglucosamine 
transferase
GH77
Amuc_1621
4-alpha-glucanotransferase 6.14 ko00500
Starch and sucrose 
metabolism
GT51
Amuc_2122 Glycosyl transferase family 
51 6.09
Amuc_0756 ADP-L-glycero-D-manno-
heptose-6-epimerase 6.01 ko00540
Lipopolysaccharide 
biosynthesis
Amuc_1880 Isocitrate dehydrogenase 
[NADP] 5.97
ko00020;ko00480 Citrate Cycle (TCA cycle); 
Glutathione metabolism
Amuc_0523
KpsF/GutQ family protein 5.91
ko00540;ko01100
Lipopolysaccharide 
biosynthesis; Metabolic 
pathways
GH16
Amuc_2108 Glycoside hydrolase family 
16 5.86
GH88
Amuc_0863 Glycosyl hydrolase family 
88 5.86
GH16
Amuc_0875 Glycoside hydrolase family 
16 5.71
GH43
Amuc_0698
Beta-glucanase 5.65
GH20
Amuc_1669 Beta-N-
acetylhexosaminidase 5.52
ko00511;ko00520
Other glycan degradation; 
Amino sugar and 
nucleotide sugar 
metabolism
GH27
Amuc_1187
Alpha-galactosidase 5.47
ko00052;ko00561 Galactose metabolism; 
Glycerolipid metabolism
Amuc_1572 2-methylcitrate 
synthase/citrate synthase II 5.43
ko00020;ko00630
Citrate Cycle (TCA cycle); 
Glycoxylate and 
dicarboxylate metabolism
Amuc_1756 Phosphoenolpyruvate-
protein phosphotransferase 5.42 ko02060
Phosphotransferase system 
(PTS)
GH20
Amuc_0369 Beta-N-
acetylhexosaminidase 5.41
ko00511;ko00520
Other glycan degradation; 
Amino sugar and 
nucleotide sugar 
metabolism
GH20
Amuc_1924 Beta-N-
acetylhexosaminidase 5.41
Amuc_1242 Inositol-phosphate 
phosphatase 5.24
ko00521;ko00562
Streptomycin biosynthesis; 
Inositol phosphate 
metabolism
GH29
Amuc_0010
Alpha-L-fucosidase 5.00 ko00511 Other glycan degradation
GH36
Amuc_0517
Raffinose synthase 5.00
GH43
Amuc_0697
Beta-glucanase 5.00
GT2
Amuc_0757 Glycosyl transferase family 
2 5.00
GH109
Amuc_0920 Glycosyl hydrolase family 
109 protein 2 5.00
GH97
Amuc_1420 Putative uncharacterized 
protein 5.00
GT2
Amuc_1582 Glycosyl transferase family 
2 5.00
Amuc_1616
Polysaccharide deacetylase 5.00
GH13
Amuc_1637 Alpha amylase catalytic 
region 5.00
GH2, CBM32
Amuc_1667 Glycoside hydrolase family 
2 sugar binding 5.00
GH20
Amuc_1815 Beta-N-
acetylhexosaminidase 5.00
GH20
Amuc_2018 Beta-N-
acetylhexosaminidase 5.00
ko00511;ko005
20;ko00531
Other glycan degradation; 
Amino sugar and 
nucleotide sugar 
metabolism
CAZy Locus tag Protein
Average_LFQ_
Human Milk KO ID Pathway
Table 1.  Abundance of A. muciniphila enzymes involved in carbohydrate metabolism with their corresponding 
KEGG identifier (KO ID). The average of Log10 transformed LFQ values is shown. Colouring is based on 
abundance from the most abundant (red) to medium abundant (orange) to least abundant (green).
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:14330  | https://doi.org/10.1038/s41598-020-71113-8
www.nature.com/scientificreports/
A. muciniphila expresses mucus-utilisation enzymes to consume human milk oligosaccha-
rides. Akkermansia muciniphila is adept at mucus glycans degradation and we showed in this study that A. 
muciniphila was able also to utilise human milk glycans. Thus, we investigated whether the enzymatic capacity 
is adapted to the different environmental conditions. Consequently, we compared the protein expression profile 
between A. muciniphila grown on human milk and grown on mucin.
First, we tested the activity of A. muciniphila cell lysates by measuring α-fucosidase, β-galactosidase and 
sialidase activities from cultures grown in either human milk or mucin. The lysates from mucin- and human 
milk cultures were incubated with synthetic substrates and both demonstrated fucosidase, β-galactosidase and 
sialidase activity. Human milk cell lysates showed significantly higher β-galactosidase and sialidase activity than 
in mucin lysates (Fig. 4a,b). Fucosidase activity was similar for both human milk and mucin (Fig. 4c). The cell 
lysates were also incubated with lactose or 2′-FL. Samples were taken at 0, 20 h and analysed by HPAEC-PAD. 
The lysates from A. muciniphila grown both on human milk and mucin showed partial degradation of lactose into 
its constituent monosaccharides (glucose and galactose) and partial degradation of 2′-FL into lactose, glucose, 
galactose and fucose (Supplementary Fig. 6a–d).
Second, a comparative proteome study identified the enzymes of A. muciniphila that are expressed in either 
human milk or mucus conditions. A total of 832 proteins were detected in both human milk and mucin. Forty-
six proteins were significantly more abundant in human milk (p-value < 0.05), while 219 proteins more abun-
dant in mucin condition (Supplementary Fig. 7). The rest of the proteins were expressed in similar amounts 
between the two conditions. We identified 108 proteins that were involved in carbohydrate metabolic process, 
of which the majority (67%) was expressed in similar amounts in human milk and mucin (Table 3), while 36 
(33%) were significantly influenced by the environmental conditions (Supplementary Tables 5 and 6). When 
focusing on mucus glycan degradation enzymes, 42 out of the 61 annotated enzymes in the A. muciniphila pro-
teome were detected in both milk and mucin conditions (Table 3). The majority (64%) was expressed in similar 
amounts in both conditions. Three proteins were significantly more abundant in human milk (Amuc_1755 
and Amuc_1033 encoding for sulfatase activity, Amuc_0670 encoding for trypsin-like protein serine pro-
tease), and 12 proteins were more abundant in mucin condition (Amuc_1631—Carboxyl terminal protease, 
Amuc_1220—α-N-acetylglucosaminidase, Amuc_0451—Sulfatase, Amuc_0824—Glycoside Hydrolase Fam-
ily 2, Amuc_1008—Glycoside Hydrolase Family 31, Amuc_1835—Exo-α-sialidase, Amuc_1182—Sulfatase, 
Amuc_0010—α-l-fucosidase, Amuc_0369—β-N-acetylhexosaminidase, Amuc_1187—α-galactosidase, 
Amuc_1924—β-N-acetylhexosaminidase, and Amuc_1815—β-N-acetylhexosaminidase). The majority of the 
glycan-degrading enzymes were found to be carbohydrate-active enzymes belonging to the glycoside hydrolases 
(GH) family (Table 3). Finally, human milk conditions showed a higher expression of the pili-associated pro-
tein (Amuc_1100), which has been characterised as an outer membrane  protein35. All proteins of the pili gene 
cluster (Amuc_1098 – Amuc_1102), were expressed in (Amuc_1099, Amuc_1100, Amuc_1101) in higher levels 
in human milk, while Amuc_1098 was more abundant on mucin (p-value < 0.05). The results indicate that A. 
muciniphila has a highly adapted lifestyle to thrive on complex host-derived glycan structures such as the ones 
in human milk and the mucus layer, where similar enzymes are used by the organism to degrade either substrate.
Discussion
This study demonstrates that A. muciniphila can grow on human milk thanks to the expression of a set of HMO 
degrading enzymes. Human milk fermentation by A. muciniphila resulted in the degradation of fucosylated and 
sialylated HMOs (Fig. 3). We demonstrated that A. muciniphila GH29 α-fucosidase (Amuc_0010) could cleave 
the α1-2-linked fucose to galactose. However, the high KM value obtained during incubation with 2′-FL indi-
cates that this substrate might not be one of the preferred substrates for Amuc_0010. In mucus, fucose is mostly 
Table 2.  Kinetic parameters of α-L-fucosidase (Amuc_0010), β-hexosaminidases (Amuc_0369 and 
Amuc_2136) and β-galactosidases (Amuc_0771 and Amuc_1686) with synthetic substrates and HMOS.
Substrate Vmax (μM min−1) kcat  (min−1) KM (μΜ) kcat/KM  (min−1 μM−1)
a-L-fucosidase
Amuc_0010
PNP-Fucose 19.76 ± 11.30 2.27E + 04 841.23 ± 46.72 27.07
2′-Fucosyllactose 25.13 ± 6.80 152.08 1.03 × 104 ± 6.98 × 103 0.02
β-hexosaminidases
Amuc_0369
PNP-GlcNAc 55.64 ± 2.02 4.02 × 104 323.38 ± 43.64 124.50
Lacto-N-triose II 982.61 ± 37.68 1.42 × 104 3,980 ± 210.30 3.56
Amuc_2136
PNP-GlcNAc 109.46 ± 4.22 8.93 × 104 714.55 ± 47.96 125.10
Lacto-N-triose II 443.75 ± 47.20 1.45 × 104 2,435.82 ± 289.51 5.95
β-galactosidases
Amuc_0771
PNP-Galactose 60.08 ± 7.02 825.63 2,599 ± 565.27 0.34
Lacto-N-tetraose 302.08 ± 53.71 4.42 × 103 1,223 ± 171.70 3.61
Amuc_1686
PNP-Galactose 29.34 ± 3.80 1.63 × 103 319.40 ± 259.30 4.21
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found linked through α1-6 to the reducing, terminal  GlcNAc30 in O-glycans, indicating that this enzyme from 
A. muciniphila might prefer mucus glycans structures over glycosidic linkages that are present in HMOs. HMO 
content differs per person based on the expression of certain glycosyltransferases. For instance, the presence of 
terminal α1-2 fucosylated HMOs requires a functional α1-2 fucosyltransferase (FUT2), encoded by the secretor 
gene in  humans36,37. Interestingly, it was reported that A. muciniphila is more abundant in the caesarean-born 
infants of FUT2 secretor mothers than in the non-secretor  mothers38. In this study, we showed that A. mucin-
iphila can use fucose from human milk and basal media supplemented with 2′-FL as an energy source resulting 
in the production of 1,2-propanediol. This agrees with the ability of A. muciniphila to use fucose released from 
mucin. The liberation of 1,2-propanediol could lead to cross-feeding in the gut as previous studies have shown 
that 1,2-propanediol was utilised by other bacteria in the gastrointestinal  tract39–42. For instance, Eubacterium 
hallii and Lactobacillus reuteri were able to utilise 1,2-propanediol derived from the fermentation of fucose and 
rhamnose to produce  propionate39,40. In this way, the milk and mucus degrading ability of A. muciniphila would 
support microbial network formation in the early life intestine and the early life mucosal environment in the gut.
A. muciniphila encodes sialidases that could cleave the 3′-sialyllactose into lactose and neuraminic acid. The 
activity of A. muciniphila against sialylated mucus-glycans has been assessed  before43. We found that the two 
exo-α-sialidases (Amuc_0625 and Amuc_1835) were present in our proteomics dataset. The release of α2-3 and 
α2-6-linked sialic acid from sialylated HMOs 3′-SL and 6′-SL44 are therefore considered to be the result of their 
activity. Sialic acid resulting from the degradation of 3′-SL could not be further utilised by A. muciniphila, which 
could be due to the fact that it lacks the Nan cluster (NanA/K/E) that is described to be necessary for the sialic 
acid utilisation in other  microorganisms45. Both human milk and mucin are rich in terminal sialyl-groups. The 
sialidase activity of A. muciniphila enables the release of sialic acid, however it seems most likely that A. mucin-
iphila uses its sialidase activity to reach the sugars that are difficult to attain. At the same time, the released sialic 
acid could serve as substrate for community members, rather than for A. muciniphila itself. This implies a key 
role for A. muciniphila in the formation of a microbial network in the infant gut stimulating growth of bacteria 
that can use sialyl-groups and thus increasing diversity. Bifidobacterium breve’s growth, for example, is promoted 
by the sialic acid that is liberated from the degradation of sialyl-oligosaccharides in the gut by Bifidobacterium 
bifidum46,47. Additionally, Ruminococcus gnavus ATCC 29149 that is present in the digestive tract of humans 
encodes a complete Nan cluster for the sialic acid  consumption48. It has been also reported that Bacteroides fragilis 
was able to metabolise the released sialic acid in the gut via an alternative pathway (nanLET)49. To further support 
Figure 4.  Enzymatic activity of cells lysates of A. muciniphila. The activity of (a) β-galactosidases, (b) sialidases 
and (c) α-fucosidases in cell lysates was tested with 2.5 mM oNPG/pNPG, 2.5 mM MU-NA and 0.5 mM pNP-
Fuc, respectively. One unit (U) is the amount of enzyme that converts 1 μmole substrate per min.
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Table 3.  A. muciniphila’s saccharolytic enzymes. Locus tags in grey indicate the enzymes that are predicted to 
be in mucin degradation with their corresponding CAZy Family group. Positive values (Log10 Fold change) 
indicate higher abundance in human milk than in mucin condition. P-values less than 0.05 are shown in with 
light blue colour.
Locus tag Protein Log10 Fold change p-value CAZy Family
Amuc_1815 Beta-N-acetylhexosaminidase -1.74 0.00 GH20
Amuc_1924 Beta-N-acetylhexosaminidase -1.72 0.01 GH20
Amuc_1500 Polysaccharide deacetylase -1.53 0.08 CE4
Amuc_1187 Alpha-galactosidase -1.48 0.02 GH27
Amuc_0369 Beta-N-acetylhexosaminidase -1.22 0.03 GH20
Amuc_0863 Glycosyl hydrolase family 88 -1.19 0.06 GH105
Amuc_1616 Polysaccharide deacetylase -1.14 0.02 CE4
Amuc_0010 Alpha-L-fucosidase -1.13 0.03 GH29
Amuc_1686 Beta-galactosidase -1.01 0.25
GH35, 
CBM32
Amuc_1667 Glycoside hydrolase family 2 sugar binding -0.90 0.13 GH2
Amuc_1032 Beta-N-acetylhexosaminidase -0.81 0.32 GH20
Amuc_1669 Beta-N-acetylhexosaminidase -0.66 0.35 GH20
Amuc_1835 Exo-alpha-sialidase -0.57 0.01 GH33
Amuc_0060 Alpha-N-acetylglucosaminidase -0.57 0.21 GH89
Amuc_1438
Glycosyl hydrolase family 98 putave 
carbohydrate binding module -0.54 0.43 CBM51
Amuc_0186 Glycoside hydrolase family 95 -0.51 0.27 GH95
Amuc_0771 Beta-galactosidase -0.42 0.52 GH35
Amuc_1637 Alpha amylase catalyc region -0.38 0.36 GH13
Amuc_0697 Beta-glucanase -0.37 0.36 GH43
Amuc_2018 Beta-N-acetylhexosaminidase -0.35 0.36 GH20
Amuc_1008 Glycoside hydrolase family 31 -0.34 0.01 GH31
Amuc_0824 Glycoside hydrolase family 2 TIM barrel -0.32 0.01 GH2
Amuc_1220 Alpha-N-acetylglucosaminidase -0.29 0.05 GH89
Amuc_0724 Glucan endo-1,3-beta-D-glucosidase -0.18 0.77 GH16
Amuc_0290 Glycoside hydrolase family 2 sugar binding -0.14 0.12 GH2
Amuc_0625 Exo-alpha-sialidase -0.13 0.85 GH33
Amuc_2136 Glycoside hydrolase, family 20, catalyc core -0.07 0.23 GH20
Amuc_0539 Glycoside hydrolase family 2 sugar binding -0.03 0.79 GH2
Amuc_1868 Glycoside hydrolase family 57 0.00 0.97 GH57
Amuc_0698 Beta-glucanase 0.01 0.98 GH43
Amuc_0392 Coagulaon factor 5/8 type domain protein 0.03 0.54 GH29
Amuc_0235 Alpha-glucan phosphorylase 0.09 0.46 GT35
Amuc_0875 Glycoside hydrolase family 16 0.19 0.73 GH16
Amuc_2108 Glycoside hydrolase family 16 0.86 0.13 GH16
Amuc_1880 Isocitrate dehydrogenase [NADP] -1.52 0.03 -
Amuc_1480
Pepdase S11 D-alanyl-D-alanine 
carboxypepdase 1 -1.25 0.13 -
Amuc_1756 Phosphoenolpyruvate-protein phosphotransferase -1.18 0.03 -
Amuc_0756 ADP-L-glycero-D-manno-heptose-6-epimerase -1.02 0.13 -
Amuc_0391 Pepdase M23 -0.93 0.16 -
Amuc_1182 Sulfatase -0.90 0.03 -
Amuc_1543 Formate acetyltransferase -0.83 0.00 -
Amuc_0523 KpsF/GutQ family protein -0.63 0.27 -
Amuc_1436 Malate dehydrogenase -0.58 0.03 -
Amuc_0155 Phosphoglucomutase/phosphomannomutase alpha/beta/alpha domain I -0.46 0.04 -
Amuc_0451 Sulfatase -0.29 0.04 -
Amuc_1631 Carboxyl-terminal protease -0.26 0.00 -
Amuc_0491 Sulfatase -0.24 0.36 -
Amuc_0953 Sulfatase -0.19 0.09 -
Amuc_2040 Oligopepdase A -0.18 0.36 -
Amuc_1106 Pepdase M24 -0.15 0.50 -
Amuc_1074 Sulfatase -0.11 0.39 -
Amuc_1572 2-methylcitrate synthase/citrate synthase II -0.07 0.92 -
Amuc_0121 Sulfatase 0.17 0.20 -
Amuc_1033 Sulfatase 0.24 0.02 -
Amuc_1242 Inositol-phosphate phosphatase 0.24 0.17 -
Amuc_0670
Trypsin-like protein serine protease typically 
periplasmic contain C-terminal PDZ domain-
like protein 0.29 0.01 -
Amuc_0465 Pepdase M23 0.73 0.10 -
Amuc_1755 Sulfatase 1.02 0.01 -
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the cross-feeding properties of A. muciniphila, it has been observed before that A. muciniphila is stimulated 
by the presence of the butyrate producer Anaerostipes caccae when grown on mucin. Indeed, A. muciniphila 
when co-cultured with A. caccae upregulates mucin-degrading genes that can play a role in the degradation of 
oligosaccharide chains consisting of monomeric sugars such as GalNAc, GlcNAc, mannose, galactose, fucose 
and sialic  acid50.
In the proteome data, we further identified two β-galactosidases (Amuc_0771, Amuc_1686) of A. muciniphila, 
that showed similar expression between human milk and mucin cultures. The recombinantly-expressed protein 
Amuc_0771 displayed activity on lactose by releasing galactose and glucose. However, the rate of hydrolysis of the 
reaction was slow and we were unable to determine the kinetics of this enzyme on lactose. This finding is consist-
ent with that of Kosciow et al. who observed that Amuc_0771 exhibited low relative hydrolytic activity against 
β1-4 linked galactose to glucose (lactose) and β1-4 linked galactose to N-acetyl-d-glucosamine (LacNAc)51. Guo 
et al., recently characterised the enzymatic activity of an A. muciniphila GH35 β-galactosidase, Am0874. In this 
study, a different tool was used for annotation A. muciniphila’s genes that is not in any other common genome 
or proteome database (ncbi.nlm.nih.gov, genome.jp/keg, uniport.org,). When we aligned the protein sequences 
from both β-galactosidases NCBI we found a 100% identity between Amuc_0771 and Am0874. Based on their 
data we can confirm that this enzyme can hydrolyse glycosidic bonds in synthetic substrates and N-glycans. They 
pointed out that the enzyme showed higher efficiency of cleaving β1-3 and β1-6 than β1-4-linked galactose. 
Interestingly, they found that Am0874 had lower cleaving capacity when galactose was linked to GlcNAc in β1-4-
configuration compared to galactose linked in β1-3-configuration  GalNAc52. In our results this β-galactosidase 
(Amuc_0771) exhibited higher hydrolysis against β1-3-linked galactose (LNT) than β1-4 configuration (lactose). 
The other β-galactosidase (Amuc_1686) that we studied, showed no hydrolysing capacity against LNT or lac-
tose. The activity of Amuc_1686 has been characterised in another study where it is reported that the enzyme 
exhibits no activity against lactose either, but it showed preference over Galacto-N-biose (Galβ1- 3GalNAc)53. 
In the same study, it is mentioned that Amuc_1686 is able to cleave only the β1-3-linked galactose to GalNAc 
and not the β1-3-linked galactose to GlcNAc. Their findings might explain the reason why Amuc_1686 was not 
active against the β1-3-linked galactose to GlcNAc (LNT) in our experiments. A. muciniphila’s β-galactosidases 
are responsible for the liberation of the terminal galactose linked to milk’s glycan structures. The free galactose 
is consumed further by the action of a galactokinase (Amuc_0969). Surprisingly, closer analysis of the proteome 
data highlighted that A. muciniphila produced Amuc_0969 in higher amounts than Amuc_0097, indicating that 
galactose continued being utilised by A. muciniphila compared to glucose (Supplementary Table 4).
In the absence of glycoproteins from mucus A. muciniphila has an essential need for  GlcNAc54. In case of 
growth on human milk GlcNAc could be released by β-acetylhexosaminidases. Wang et al., recently described 
two A. muciniphila GH20 β-acetylhexosaminidases (Am2301 and Am2446) that were able to cleave the terminal 
GlcNAc off the N- and O-glycans, confirming its exo-activity as glycoside  hydrolases55. Our biochemical experi-
ment on the purified β-acetylhexosaminidases (Amuc_0369 and Amuc_2136) revealed that both enzymes were 
able to hydrolyse only the terminal β1-3 linked GlcNAc to lactose (LNT2) that results to the liberation of lactose 
molecule and not the GlcNAc that is located inside the HMO structure (LNT).
A. muciniphila grown on human milk led to the production of a significant amount of succinate (~ 10 mM). 
A. muciniphila uses the succinate pathway to produce propionate in the gut, as has been described  before56. 
Recently, it has been demonstrated that A. muciniphila is dependent on the presence of vitamin B12 as a cofactor 
of Methylmalonyl-CoA synthase in order to convert succinate to  propionate50,57. A. muciniphila grown on human 
milk expresses all the necessary enzymes to successfully convert succinate to propionate (Methylmalonyl-CoA 
mutase; Amuc_1984, Amuc_1983 and Methylmalonyl-CoA epimerase; Amuc_0200). It is described that in 
human milk vitamin B12 can be tightly bound to haptocorrin, and the concentration varies depending on the 
diet of the mother, especially on the intake of animal  products58. An explanation why succinate is not converted 
to propionate in human milk in our experiment could be that A. muciniphila is not efficient in using the B12 
present in human milk.
Akkermansia muciniphila grown on human milk shows significant higher abundance of the pili-protein 
(Amuc_1100) (p-value = 0.02, 1.29-fold change)59. This outer membrane pili-like protein plays an important role 
in immune regulation and enhancement of trans-epithelial resistance. Recently, it has been demonstrated that 
Amuc_1100 is able to improve gut barrier and restrain the high-fat-diet-induced obesity in  mice60. Therefore, 
expression of this protein in the infant gut might also contribute to immune maturation and gut health in early 
life.
Interestingly, the proteome analysis showed high abundance of seven sulfatases functioning as sulfate ester 
hydrolases. Four of these expressed sulfatases (Amuc_0451, Amuc_1033, Amuc_1182, Amuc_1755) were sig-
nificantly higher expressed in human milk. It has not been reported so far that HMOs could have sulfate residues 
attached to their glycan structure like in O-glycans of mucin. However, it has been described that human milk can 
contain more than 100 μmol/L of sulfate  esters61. These sulfate esters are part of the glycosaminoglycans (GAGs). 
GAGs are present in human milk (416 mg/L) and are highly sulfated linear polysaccharides constituted by 
disaccharidic units where the sugar unit is made up of an N-acteylhexosamine (GalNAc or GlcNAc)62. The most 
abundant GAGs found in human milk are chondroitin sulfate (CS) (231 mg/L) and heparin (Hep) (173 mg/L). 
Therefore, it is possible that A. muciniphila deploys its sulfatases for the hydrolysis of the sulfuric esters that are 
present in human milk glycosaminoglycans.
In this study, it is shown that A. muciniphila can grow on human milk and is able to degrade HMOs by using 
its glycan-degrading enzymes. These glycan-degrading enzymes hydrolyse the HMOs extracellularly into mono- 
and disaccharides and then the liberated sugars are imported in the cell by  transporters34. These findings allow 
us to propose a model for the utilisation of 2′-fucosyllactose, 3′-siallylactose, lacto-N-tetraose, lacto-N-triose II 
and lactose by A. muciniphila (Fig. 5). The results of the study suggest that A. muciniphila is able to survive in 
early life environment by consuming oligosaccharides coming either from the breast milk or infant formulae. 
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This might provide beneficial effects during the initial early life colonisation of A. muciniphila before it reaches 
its natural niche, the outer mucosal layer. Furthermore, the insufficient degradation of HMOs by A. muciniphila 
liberates simpler glycan structures and metabolites, which then become accessible to other beneficial bacteria. 
The milk environment also activated the expression of A. muciniphila outer membrane protein Amuc_1100 which 
could benefit the infant immune  system63,64. Human milk carries its microbiota to the infant’s intestine facilitating 
early life colonisation. Development of a healthy gut microbiota from the beginning of life with glycan-degrading 
microbes could be associated with health in later life by guiding the development of the immune system and 
protecting against  pathogens65,66. As such, A. muciniphila might be one of the key members of the early life guid-
ing healthy microbiota and immune development.
Material and methods
Bacterial growth conditions. Akkermansia muciniphila  MucT (ATCC BAA-835) was grown in basal 
medium as described  previously2. The medium was supplemented with either hog gastric mucin (0.5% w/v Type 
III, Sigma-Aldrich, St. Louis, MO, USA), which was purified by ethanol precipitation as described  previously67, 
human milk (10% v/v), 2′-fucosyllactose (2′-FL, 10 mM, purity > 90%) or 3′-sialyllactose (3′-SL, 10 mM, purity 
> 90%). The growth conditions containing HMOs (i.e. 2′-FL and 3′SL) were supplemented with 25 mM N-acetyl-
glucosamine (GlcNAc) as nitrogen source for A. muciniphila (Sigma-Aldrich). The bottles containing human 
milk and HMOs were further supplemented with l-Proline and l-Threonine (Sigma-Aldrich) (6 g/L). All the 
anaerobic bottles were supplemented with 1% v/v of  CaCl2 and vitamin mixture as described  previously68. 
Human breast milk was collected under sterile conditions from a healthy donor (approximately 3–6 months 
post-partum) and stored at − 20 °C until use. Incubations were completed in serum bottles sealed with butyl 
rubber stoppers at 37 °C under anaerobic conditions provided by a gas phase of 182 kPa (1.5 atm)  N2/CO2T. The 
bacterial growth on mucin by measuring the optical density at 600 nm and quantitative Polymerase Chain Reac-
Figure 5.  Schematic representation of the proposed pathway for the metabolism of pure 2′-fucosyllactose, 
3′-sialyllactose, lacto-N-tetraose, lacto-N-triose II and lactose by A. muciniphila. The proteins in green colour 
represent α-fucosidases, in orange represent sialidases, in red represent β-galactosidases and in blue represent 
β-N-acetylhexosaminidases. fucP l-fucose transporter, T putative substrate transporter.
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tion (qPCR). The optical density of the cultures of A. muciniphila grown in human milk could not be determined 
due to the high turbidity of the milk. Therefore, bacterial numbers were solely measured by qPCR.
Quantitative real-time pcR (qpcR). The abundance of A. muciniphila in human milk and mucin was 
determined by qPCR as described  previously10. Cells (1  mL) were harvested at 21,000 × g for 15  min. DNA 
extractions were performed using the MasterPure™ Gram Positive DNA Purification Kit (Epicentre, Lucigen, 
USA). DNA concentrations were measured fluorometrically (Qubit dsDNA BR assay, Invitrogen) and adjusted 
to 1 ng/μL prior to use as the template in qPCR. Primers targeting the 16S rRNA gene of A. muciniphila (AM1 
5′-CAG CAC GTG AAG GTG GGG AC-3′ and AM2 5′-CCT TGC GGT TGG CTT CAG AT-3′; 327 bp 10) were used 
for quantification. A standard curve was prepared with nine standard concentrations from  100 to  108 gene cop-
ies/μL. qPCR was performed in triplicate with iQ SYBR green supermix (Bio-Rad, USA) in a total volume of 10 
μL prepared with primers at 500 nM in 384-wells plates with the wells sealed with optical sealing tape. Ampli-
fication was performed with an iCycler (Bio-rad): one cycle of 95 °C for 10 min; 40 cycles of 95 °C for 15 s, 60° 
C for 20 s, and 72 °C for 30 s each; one cycle of 95 °C for 1 min; and a stepwise increase of temperature from 60 
to 95 °C (at 0.5 °C per 5 s) to obtain melt curve data. Data were analysed using Bio-Rad CFX Manager 3.0. The 
copy number was corrected for the DNA concentration and for the number of 16S rRNA genes encoded in A. 
muciniphila’s genome.
Human milk oligosaccharide extraction. HMOs were recovered from 1 mL aliquots of A. muciniphila 
grown in 10% v/v human milk cultures as described  before69. An internal standard of 1,5-α-l-arabinopentaose 
(Megazyme, Ireland) was added, at the volume of 10 μL per sample to minimize pipetting error, to reach a final 
concentration of 0.01 mmol/L. The solution was diluted 1:1 with ultrapure water and centrifuged at 4,000 × g for 
15 min at 4 °C. The supernatant was filtered through 0.2 μm syringe filter followed by subsequent centrifugation 
with a pre-washed ultra-filter (Amicon Ultra 0.5 Ultracel Membrane 3 kDa device, Merck Milipore, USA) at 
14,000 × g for 1 h at room temperature. Finally, the filtrate was vortexed and stored at − 20 °C.
electrospray ionisation liquid chromatography mass spectrometry (Lc-eSi-MS2) analy-
sis. HMOs were identified and quantified with LC-ESI-MS269. This method allows the study of distinct HMO 
structures more in particular their monosaccharide sequence, glycosidic linkage and the molecular conforma-
tion. Thereby the HMOs isobaric isomers such as Lacto-N-fucopentaose (LNFP) I, II, III and V could be dis-
tinguished as described by Mank et  al.69. We used the latter approach with adaptations. Micro LC-ESI-MS2 
analysis was performed on a 1,200/1,260 series HPLC stack (Agilent, Waldbronn, Germany) consisting of sol-
vent tray, degasser, binary pump, autosampler and DAD detector coupled to a 3,200 Qtrap mass spectrometer 
(ABSciex, USA). After extraction of HMOs, 2.5 μL of this extract was injected into the LC–MS system. Oligosac-
charides were separated by means of a 2.1 × 30 mm Hypercab porous graphitized carbon (PGC) column with a 
2.1 × 10 mm PGC pre-column (Thermo Scientific, USA) using a water–methanol gradient for 30 min, and 2 min 
equilibration. Solvent A consisted of 0.3% ammonium hydroxide solution (28–30%, Sigma-Aldrich, St. Louis, 
Missouri United States) in water and solvent B of 0.3% ammonium hydroxide solution in 95% methanol (all v/v). 
Pre-equilibration was performed using 97.5% solvent A. The gradient started with 97.5% solvent A for 0.5 min, 
decreased to 60% in 12.5 min and decreased to 40% in 3 min, where it was kept for 4 min. In a next segment, 
solvent A decreased in 0.5 min to 2.5% where it was kept for 3 min. In 0.5 min, solvent A increased to 97.5% for 
re-equilibration of 6 min. Eluent flow was 400 μL/min and the columns were kept at 45 °C. The LC-effluent was 
infused online into the mass spectrometer and individual HMO structures were analysed semi-quantitatively 
by multiple reaction monitoring (MRM) in negative ion mode. Specific MRM transitions for neutral HMOs 
up to pentaoses and acidic HMOs up to trioses were included. The spray voltage was − 4500 V, the declustering 
potential and collision energy were optimized to individual compounds measured. A segmented method was 
used to obtain higher sensitivity. Each MRM-transition was measured for 70 ms. The instrument was calibrated 
with polypropylene glycol (PPG) according the instruction of the manufacturer.
protein extraction from A. muciniphila cultures. Akkermansia muciniphila was grown in basal 
medium supplemented with 0.5% purified mucin or 10% human milk (4 biological replicates). After 15 and 
48 h incubation at 37 °C, cells (2 mL) were pelleted at 4,816 × g for 30 min at 4 °C, re-suspended in 1 mL PBS, 
washed twice (21,130 × g at 4 °C), and finally re-suspended in 500 µL lysis buffer (100 mM Tris HCl, pH 8.0, 4% 
(w/v) SDS, 7.7 mg/mL Dithiotreitol [DTT]). Cells were lysed by sonication (four pulses of 20 s with 30 s rest 
on ice) with an amplitude of 20–30% on ice using an MS-72 probe, followed by centrifugation at 21,130 × g for 
30 min at 4 °C. Qubit® Protein Assay Kit (Life technologies, Oregon, USA) was used according to the manufac-
turer’s instructions to determine the protein content of cell extracts. Protein samples (15 h for mucin and 48 h 
for human milk samples) (40 μg) were loaded on a Bolt 4–12% Bis–Tris Plus separation gel (Invitrogen, Life 
Technologies, USA) using the XCell Surelock Mini-Cell (Novex, Life Technologies, USA). The electrophoresis 
procedure was according to the manufacturer’s instructions. Gels were stained overnight using QC Colloidal 
Coomassie Blue G250 stain (Bio-rad Laboratories, USA).
In-gel digestion identification and relative quantification of proteins from A. muciniphila cell 
extracts. Each of the used gel lanes was cut into three slices to increase the number of identified proteins. 
Slices were further processed to pieces of about 1 mm2 and put in 1.5 mL low binding tubes (Eppendorf) prior 
to their reduction, alkylation, and trypsin digestion, as described  previously70. The supernatant obtained was 
used for LC–MS/MS analysis. Samples were measured by nLC–MS/MS with a Proxeon EASY nLC and a LTQ-
Orbitrap XL mass spectrometer as previously  described71,72. LC–MS data analysis was performed as described 
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 previously70,73,74 with false discovery rates (FDRs) set to 0.01 on peptide and protein level, and additional result 
filtering (minimally two peptides necessary for protein identification of which at least one is unique and at 
least one is unmodified). Any remaining hits against the reversed database as well as all human proteins were 
removed. To analyse the abundance of proteins in the fractions, their label-free quantification (LFQ) intensities 
were  compared75. Non-existing LFQ intensity values due to not enough quantified peptides were substituted 
with a value slightly lower than the lowest LFQ intensity value measured. The normal logarithm was taken from 
protein LFQ MS1 intensities as obtained from MaxQuant. Relative protein quantitation of sample to control 
was done with  Perseus76 by applying a two sample T-test using the “LFQ intensity” columns obtained with FDR 
set to 0.01 and S0 set to 1. nLC-MSMS system quality was checked with  PTXQC77 using the MaxQuant result 
files. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the 
 PRIDE78 partner repository with the dataset identifier PXD011357. All the A. muciniphila proteins differentially 
expressed between milk and mucin conditions are listed in Supplementary Tables 5 and 6.
Cloning, expression and purification of selected A. muciniphila glycoside hydrolases. The 
selected proteins coded by the genes with locus tags Amuc_0010 (57.51  kDa), Amuc_0369 (72.02  kDa), 
Amuc_0771 (70.53 kDa), Amuc_1686 (85.71 kDa), and Amuc_2136 (81.59 kDa) without their signal peptides 
were cloned into the pCDF-1b vector, introducing a 6xHis-tag at the C-terminus. The genes of interest and 
the plasmid backbone were amplified by PCR with gene-specific primers, using Q5 DNA polymerase (New 
England BioLabs, USA) (Supplementary Table 1). The amplified genes and vector were being assembled with 
NEBuilder HiFi DNA Assembly Master Mix (NEB BioLabs, USA) according to manufacturer’s instructions. E. 
coli DH5-aplha competent cells were transformed using 5 μL of assembly reaction and sequences were verified 
by DNA sequencing by Eurofins (Ebersberg, Germany). E. coli BL21 Rosetta competent cells were transformed 
with the recombinant plasmid harbouring the genes of interest. The recombinant cells were grown to an  OD600 
between 0.5 and 0.6 in 250 mL Lysogeny–Broth (LB) supplemented with 50 μg/mL spectinomycin and 25 μg/
mL chloramphenicol. Then, they were induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 
22 °C for 16 h. The cells were harvested by centrifugation at 6,000 × g for 20 min and re-suspended in 15 mL of 
lysis buffer. Cells were lysed by sonication on ice (1 s pulse with 2 s rest for 10 min, amplitude of 20–25%) using 
a MS-72 microtip (Bandelin, Germany). The lysate was cleared by centrifugation at 120,000 × g for 1 h at 4 °C. 
The proteins were His-tag purified using  Ni2+-nitrilotriacetate (Ni–NTA) agarose affinity columns (500 µL bed 
volume, Qiagen) equilibrated with binding buffer. Samples were loaded, followed by 2 mL of binding buffer 
and 2 × 500 µL plus 1 mL of elution buffer. Purity of the enzymes was checked by SDS-Page (4–10% polyacryla-
mide gel) (Supplementary Fig. 2) and pure samples were concentrated using 50-kDa MWCO Amicon Ultra-15 
Centrifugal Filter Units (Merck, Germany) with storage buffer. Protein content was measured using the Qubit 
Protein Assay (manufacturer’s protocol) and fluorometer (DeNovix, USA). pCDF-1b empty vector was cloned, 
expressed and purified as it is described above. The empty vector was used as negative control in all the enzy-
matic assays.
Activity assays and kinetics. The purified enzymes were incubated with different substrates in McIlvaine 
buffer solution adjusted to the optimum pH of each enzyme at 37 °C. To quantify α-fucosidase, β-galactosidase 
and β-acetylhexosaminidase activity on synthetic substrates, 4-nitrophenyl-a-l-fucopyranoside (pNP-α-l-Fuc), 
4-nitrophenyl-b-d-galactopyranoside (pNPG) and 4-nitrophenyl 2-acetamido-2-deoxy-b-d-glucopyranoside 
(GlcNAc-β-pNP) were used respectively. The enzymes were incubated with substrate concentrations ranging 
from 0 to 5 mM in McIlvaine buffer. At intervals of 2.5 min, samples were taken and added to 2.5 × volume 
of glycine buffer (pH 9.6) to stop the reaction. Absorbance was monitored at 405 nm and quantified using a 
standard curve of 4-Nitrophenol (pNP). To determine the optimal pH of each enzyme, the assay was carried 
out in McIlvaine buffer with pH values ranging from 5.0 to 8.2 and a substrate concentration of ~ 3 times the 
 KM as determined at the initial pH. Next, the aforementioned assays with 0–5 mM substrate were repeated at 
the optimal pH. For incubations of β-galactosidases and hexosaminidases with lactose and LNT, the assays were 
performed in a similar way, but the products were monitored by HPAEC-PAD. The sugars were separated by 
HPAEC with 10 mM NaOH at 0.5 mL/min on a CarboPac PA20 protected with a guard column and detected 
using PAD on a Dionex ICS5000 system (Thermo Scientific). The column was cleaned for 10 min with 200 mM 
NaOH and re-equilibrated with 10 mM NaOH. Standards of galactose and glucose in different concentrations 
were used to quantify the results. For incubations of the α-fucosidase with 2′-FL, reactions were performed in a 
similar way, but the fucose release was measured directly (without adding glycine buffer first) by α-l-fucose kit 
(Megazyme, Ireland) based on a fucose dehydrogenase-coupled  method79. Reactions without enzyme and with 
only the purified plasmid incubated in both synthetic and human milk derived sugars were served as negative 
controls. Kinetic data of the enzymes were obtained from triplicate experiments, and the kinetic parameters 
were calculated by fitting the initial raw data to the Michaelis–Menten equation using linear regression analysis, 
and the error bars (SD).
cell lysate activity. Enzymatic activity of A. muciniphila cell lysates was tested with colorimetric sub-
strates as described  previously80. The following substrate/enzyme combinations were used: 4-nitrophenyl-α-
l-fucopyranoside/fucosidase (pNP-Fuc), 4-nitrophenyl-β-d-galactopyranoside (pNPG) and 2-nitrophenyl-
β-d-galactopyranoside (ONPG)/β-galactosidase, and 2′-(4-methylumbelliferyl)-α-d-N-acetylneuraminic 
acid (MU-NA)/sialidase. Reactions were performed in a final volume 20 µL, using 0.5–2.5 mM substrate and 
~ 1 µg/mL enzyme in 0.05 M citrate buffer pH 6.0 (fucosidase, sialidase) or 0.25 M phosphate buffer, pH 7.0 
(β-galactosidase). After 1 h of incubation at 37 °C, reactions were stopped by adding 50 µL 0.5 glycine buffer, pH 
9.6. Absorbance was read at 405 nm (pNPG and pNP-Fuc) or 420 nm (oNPG) and fluorescence intensity was 
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measured at λex 390 nm, λem 460 nm on a 96-well plate reader (Biotek, USA). Activity is expressed in units (U), 
in which one unit is the amount of enzyme that converts 1 µmole substrate per minute. To test fucosidase and 
galactosidase activity of cell lysates in 2′-FL and lactose, ~ 10 µg/mL of each enzyme was incubated with 1 mM 
lactose and 1 mM of 2′-FL in 0.05 mM citrate buffer, pH 6.0 in a final volume of 1 mL, shaking at 300 rpm. Reac-
tions of aliquots at different time points were stopped by adding 2.5 × the volume of 0.5 M glycine buffer, pH 9.6. 
The reaction was monitored by HPAEC-PAD as it was described previously.
High-performance liquid chromatography. For fermentation product analysis, samples were obtained 
at different time points of the incubation period. Crotonate was used as the internal standard and the external 
standards were lactate, formate, acetate, propionate, butyrate, succinate, 1,2-propanediol, lactose, N-acetyl-glu-
cosamine (GlcNAc), N-acetyl-galactosamine (GalNAc), 2′-fucosyllactose (2′-FL), 3′-sialyllactose (3′-SL), glu-
cose, galactose, fucose and sialic acid. Substrate conversion and product formation were measured with Thermo 
Scientific Spectrasystem high-performance liquid chromatography (HPLC) system equipped with a Varina Met-
acarb 67H 300 × 6.5 mm column kept at 45 °C and running 0.0005 mM sulfuric acid as eluent. The eluent had a 
flow of 0.5 mL/min and metabolites were detected by determining the refractive index (RI-150) and identified 
by using standards of pure compounds as described  previously81.
Statistical analysis. Statistics were performed using student’s t-test and corrected for multiple testing using 
False Discovery Rate (FDR). Data are presented as mean ± standard deviation (SD), unless stated otherwise. 
P-values below 0.05 were considered significant.
ethical consideration. The usage and analysis of human milk samples described in this study were per-
formed with written consent by the donor.
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